RAMM PHARMA CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.04 CAD | 0.00% |
|
-33.33% | -27.27% |
| Mar. 29 | RAMM Pharma Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024 | CI |
| Mar. 19 | RAMM Pharma Corp. cancelled the transaction announced on September 5, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 3.9M 2.83M | Sales 2023 | 5.07M 3.68M | Capitalization | 5.97M 4.34M |
|---|---|---|---|---|---|
| Net income 2022 | -21M -15.27M | Net income 2023 | -7M -5.09M | EV / Sales 2022 | 3.95 x |
| Net cash position 2022 | 9.09M 6.61M | Net cash position 2023 | 4.71M 3.43M | EV / Sales 2023 | 0.25 x |
| P/E ratio 2022 |
-1.17
x | P/E ratio 2023 |
-0.78
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 73.72% |
More Fundamentals
* Assessed data
More news
| 1 week | -33.33% | ||
| Current month | -33.33% | ||
| 1 month | -38.46% | ||
| 3 months | -11.11% | ||
| 6 months | -42.86% | ||
| Current year | -27.27% |
1 week
0.04
0.04
1 month
0.040.07
Current year
0.000.07
1 year
0.000.11
3 years
0.001.02
5 years
0.001.19
10 years
0.001.19
| Managers | Title | Age | Since |
|---|---|---|---|
Jackie Burnett
CEO | Chief Executive Officer | - | 19-09-30 |
José Roldan
DFI | Director of Finance/CFO | - | 22-12-08 |
Edelma Ros
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eric Klein
BRD | Director/Board Member | 64 | 19-09-30 |
Daniel Augereau
BRD | Director/Board Member | 80 | 19-09-30 |
Jackie Burnett
CEO | Chief Executive Officer | - | 19-09-30 |
| Date | Price | Change | Volume |
|---|
Delayed Quote Canadian Securities Exchange, May 02, 2024 at 02:38 pm EDT
More quotes
RAMM Pharma Corp. is a Canada-based company that is engaged in the pharmaceutical and medical product business, including cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other hemp-based products with a diversified international production and sales platform. The Company operates a pharmaceutical and medical product business in Uruguay that has developed several medically registered and approved plant-derived cannabinoid pharmaceutical products that have been authorized for sale and/or use in several Latin American countries. The Company has a pipeline of products, including registered hemp-based nutrition and specialized veterinary products, in various stages of approval and development, which are produced at its formulation facility in Montevideo, Uruguay. The Company's brands include NettaPet and NettaVet. Its subsidiaries include Canapar Corp., HemPoland S.p. Z.o.o., Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.
Calendar
2024-06-24
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -27.27% | 3.49M | |
| +21.74% | 46.4B | |
| -0.97% | 41.75B | |
| +47.07% | 41.37B | |
| -3.52% | 29.71B | |
| +11.12% | 26.01B | |
| -19.37% | 19.52B | |
| +31.18% | 12.43B | |
| -0.04% | 12.13B | |
| +0.39% | 12.18B |
- Stock Market
- Equities
- RAMM Stock